Join the Eosinophilic Esophagitis group to help and get support from people like you.
Eosinophilic Esophagitis News
Related terms: EE
Histologic Response Up With Benralizumab for Eosinophilic Esophagitis
WEDNESDAY, June 26, 2024 – Benralizumab yields a greater histologic response than placebo for patients with eosinophilic esophagitis, but does not affect dysphagia symptoms, according to a study...
Dupilumab Ups Histologic Response for Pediatric Eosinophilic Esophagitis
THURSDAY, June 27, 2024 – For children with eosinophilic esophagitis, dupilumab results in a significantly higher percentage of histologic remission, according to a study published in the June 27...
FDA Approves Eohilia for Eosinophilic Esophagitis
FRIDAY, Feb. 16, 2024 – The U.S. Food and Drug Administration has approved Eohilia (budesonide oral suspension) as the first and only oral treatment for eosinophilic esophagitis (EoE). The oral...
FDA Approves Eohilia (budesonide oral suspension) for the Treatment of Eosinophilic Esophagitis
OSAKA, Japan and CAMBRIDGE, Massachusetts, February 12, 2024 – Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved Eohilia (budesonide oral s...
FDA Approves Dupilumab for Children With Eosinophilic Esophagitis
MONDAY, Jan. 29, 2024 – The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of pediatric patients (aged 1 to 11 years) with eosinophilic esophagitis (EoE). This...
Dupixent (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
TARRYTOWN, N.Y. and PARIS, Jan. 25, 2024 (GLOBE NEWSWIRE) – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved...
American College of Chest Physicians, Oct. 8-11
The annual meeting of the American College of Chest Physicians was held this year from Oct. 8 to 11 in Honolulu and attracted participants from around the world, including specialists and heath care...
New Clues to Treating a Disease That Prevents Children From Swallowing, Eating
TUESDAY, Aug. 1, 2023 – Children who have a chronic immune system disease that can prevent them from eating may eventually have a new treatment, decades after the condition was first identified....
FDA Approves Dupixent (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis
Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months ahead of FDA's Priority Review action date Dupixent...
Ask a question
To post your own question to this support group, sign in or create an account.